Urokinase for injection is a white or quasi-white amorphous powder.
Urokinase for injection is mainly used for thrombolytic therapy of
thromboembolic diseases.
Urokinase for injection acts directly on the endogenous fibrinolytic system
and catalyzes the lysis of plasminogen into fibrinolytic enzyme, which not only
degrades fibrinogen clots, but also degrades fibrinogen, coagulation factor Ⅴ
and coagulation factor in blood circulation, so as to play a role in
thrombolysis. Injectable urokinase responds quickly to a newly formed
thrombus.
1. Urokinase for injection can improve vascular ADP enzyme activity,
inhibit ADP-induced platelet aggregation, and prevent thrombosis.
2. After intravenous infusion of urokinase, the activity of plasminase in
patients was significantly increased; A few hours after drug withdrawal,
plasminase activity returned to its original level. However, the decrease in
plasma fibrin or fibrinogen levels and the increase in their degradation
products can last for 12 to 24 hours.
3. Urokinase for injection showed obvious correlation between thrombolytic
effect and drug dose and time window of administration.
4. The toxicity of urokinase for injection is very low, and the 50% lethal
dose of intravenous injection in mice is more than 1 million IU/kg body weight.
There is no obvious antigenicity, teratogenicity, carcinogenicity and
mutagenicity.
5. Clinical application of urokinase for injection rarely has allergic
reaction reported. However, since this product increases plasminogen activity
and reduces unbound plasminogen and fibrin-bound plasminogen in circulation,
there may be a serious risk of bleeding.
Above is the relevant content summarized by Kang Yuan's editor. If you want
to know more, please follow us. We will update you regularly about Human
Chorionic Gonadotropin, Human Menopausal Gonadotropin supplier, Urofollitropin
price, Urokinase manufacturer, Hormone API manufacturer.